Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of sofosbuvir-based regimens in patients with chronic HCV infection and compensated or decompensated cirrhosis: A Gilead Cirrhosis Registry study

Trial Profile

Safety and Efficacy of sofosbuvir-based regimens in patients with chronic HCV infection and compensated or decompensated cirrhosis: A Gilead Cirrhosis Registry study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results (As of 5 OCT 2017; n=1564) assessing long-term outcomes in patients with cirrhosis who achieved SVR following treatment with a sofosbuvir based regimen, presented at the Digestive Disease Week 2018
    • 16 May 2018 New trial record
    • 14 Apr 2018 Results (n=1564; as of 5 OCT 2017) presented at The International Liver Congress 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top